Thus, our study shows a new research direction for improving the immune efficacy of RCC in PBRM1 wild‐type patients and greatly improves the possibility of using targeted peptides in the clinical treatment of PBRM1 wild‐type patients. Here, PBRM1 is linked to renal cell carcinoma.